Sensitivity to taxoid derivatives of a newly established human endometrioid ovarian adenocarcinoma radioresistant cell line

Anticancer Research

Volumn 16, Issue 1, 1996, Pages 177-188

  Griffon, Genevieve ^a   Merlin, Jean Louis ^a   Parache, Robert M ^a   Martinet, Nadine ^b   Marchal, Sophie ^a   Nabet, Francine ^c   Wellman, Maria ^d   Barlier, Catherine ^e   Marchal, Christian ^a  

^a CENTRE ALEXIS VAUTRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

^d Centre du Medicament URA CNRS 597   (France)

^e Laboratoire d'Anatomie Pathologique   (France)

Author keywords

Cisplatin; Glutathione; Ovarian tumor; Radiosensitivity; Taxoid

Indexed keywords

CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PACLITAXEL; PACLITAXEL DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASE REPORT; CHROMOSOME ANALYSIS; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; KARYOTYPE; MONOLAYER CULTURE; MOUSE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RADIOSENSITIVITY; TRIPLOIDY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BASE SEQUENCE; CARCINOMA, ENDOMETRIOID; CELL DIVISION; DNA, NEOPLASM; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLOW CYTOMETRY; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; KARYOTYPING; MICE; MICE, NUDE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PLOIDIES; RADIATION TOLERANCE; RNA, MESSENGER; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0029986597     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Lansac J, Lefloch O, Fetissof F, Lemarie E and Bougnoux P: Cancers de l'ovalre. In. Y Rochet, C Lagarde and A Brémond (eds), Cancers gynécologiques et mammaires. Flammarion Medecine Sciences Paris, 1986, pp. 175-225..
2. Averette HE and Donato DM: Ovarian carcinoma. Advances in diagnosis, staging, and treatment. Cancer 65: 703-708, 1990.
3. Hill BT, Whelan RDH, Gibby EM, Sheer D, Harking LK, Shellard SA and Rupniak HT: Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies. Int J Cancer 39: 219-225, 1987.
4. Nicoletti MI, Lucchini V, D'Incalci M and Giavazzi R: Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 30A: 691-696, 1994.
5. Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71: 644-649, 1993.
6. Slotman BJ., Karim ABMF and Rao BR: Ovarian cancer: radiation sensitivity in vitro. Radiother Oncol 19: 323-327, 1990.
7. Bast R.C, Feeney, M, Lazarus M, Nadler LM, Colvin RB, and Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68 1331-1337, 1981.
8. Trent JM, Thompson FH and Buick RN: Generation of clonal variants in a human ovarian carcinoma studied by chromosome banding analysis. Cancer Genet Cytogenet 14: 153-161, 1985.
9. Van den Berg-Bakker CAM, Hagemeijer A, Franken-Postma, E, Smit VTHM, Kuppen PJK, van Ravenswaay Claasen HH, Cornelisse, CJ and Schrier PI: Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 53: 613-620, 1993.
10. Ganter P and Jolles G: Coloration cytologique, In: (Ganter P and Jolles G (eds), Histochimie normale et pathologique. Gautier-Villars, Paris. 1970, Vol 2, pp. 1435-1436.
11. Wood GS and Warnke R: Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. J Histochem Cytochem 29: 1196-1204, 1984.
12. Merlin JL, Chastagner P, Marchal C, Weber B and Bey P: In vitro combination of high dose busulfan with radiotherapy on medulloblastoma cells: additive effect without potentiation. Anti-Cancer Drugs 2: 465-468, 1991.
13. Hamburger AW and Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463: 1977.
14. Vindelov LL, Christensen IJ and Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3: 323-327, 1983.
15. Trent JM, Davis JR and Payne CM: The establishment and morphologic characterisation of finite cell lines from normal human endometrium. Am J Obstet Gynecol 136: 352-362, 1980.
16. Caspersson T, Zech L, Johanson C and Modest FJ: Identification of human chromosomes by DNA - Binding fluorescent agents. Chromosome 30: 215-227, 1970.
17. ISCN, Report on the standing committee on human cytogenetic nomenclature. In: Harnden DG and Klinger HP (eds), Cancer Cytogenet suppl to An International System for Human Cytogenetic Nomenclature. Karger, Basel, 1991.
18. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesh H, Kenney S and Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
19. Chou TC and Talalay P: Quantitative analysis of dose effect relationship: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27, 1984.
20. Carmichael J, Degraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res 47: 943-946, 1987.
21. Fertil, B and Malaise EP: Inherent cellular radiation as a basic concept for human tumor radiotherapy. Int J Radiat Oncol Biol Phys 7: 621-629, 1981.
22. Fertil B, Dertinger H, Courdi A and Malaise EP: Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiat Res 99: 73-84, 1984.
23. Chirgwin JM, Przybyla AE, MacDonald RJ and Rutter WJ: Isolation of biologically active ribonuclcic acid from sources enriched in ribonuclease. Biochemistry 18: 5294-5299, 1979.
24. Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman CL, Griffith B, Von Hoff DD and Roninson IB: Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 87: 7160-7164, 1990.
25. Schiele F, Muller J, Colinet E and Siest G: Production and certification of an enzyme reference material for γ-glutamyltransferase (CRM 319). Part 2: certification campaign. Clin Chem 33: 1971-1977: 1987.
26. Habig WH, Pabst MJ and Jakoby WB: Glutathione S-Transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 249: 7130-7139, 1974.
27. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem 150: 265-275, 1951.
28. Paglia DE and Valantine WW: Studies on the quantitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70 158-169, 1967.
29. Yuhas, JM, Li, AP, Martinez, AO, and Landman, AJ. A simplified method for production and growth of multicellular tumor spheroids. Cancer Res 37,. 3639-3643, 1977.
30. Moll R, Pitz S, Levy R, Weikel W, Franke WW and Czernobilsky B: Complexity of expression of intermediate filamants, including glial filamant protein, in endometrial and ovarian adenocarcinomas. Hum Pathol 22: 989-1001, 1991.
31. Moll R, Franke WW and Schiller DL: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31: 11-24, 1982.
32. Van Niekerk CC, Ramaekers FCS, Hanselaar AGJM, Aldeweireldt J and Poels LG: Changes in expression of differentiation markers between normal ovarian cells and derived tumors. Am. J. Pathol 142: 157-177, 1993.
33. Latza U, Niedobitek G, Schwarting R, Nekarda H and Stein H: BerEP4: New monoclonal antibody which distinguishes epithelia from mesothelia. J Clin Pathol 43: 213-219, 1990.
34. Klug TL, Bast RC, Niloff JM, Knapp RC and Zurawski VR: Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinoma. Cancer Res 44: 1048-1053, 1984.
35. Griffon G, Merlin JL, Parache RM, Leroux-Broussier A, Marchal S and Marchal C: Radiosensitivity of spheroids obtained from human ovarian tumors: preliminary results. In: Drugs, cells and cancer, Dittrich CH, Arps H and Aapro MS (eds), EORTC Preclinical Therapeutic Models Group, 1992 Annual Report, Welley, G, Vienna, 1992, pp 42-47.
36. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC and Colvin RB. Tissue distribution of a coelomic epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol 2: 275-285, 1983.
37. Herman CJ, Vooys GP, Baak JPA and Boon ME: Quantitative cytologic and histologic techniques to assist in cancer evaluation, In Meth. Achiev. exp. Path. (Jasmin G and Proschek L, eds.), 11: 73-95, 1984.
38. Braly PS and Klevecz, RR: Flow cytometric evaluation of ovarian cancer Cancer 71: 1621-1628, 1993.
39. Barlogie B, Johnston DA, Smallwood L, Raber MN, Maddox AM, Latreille J, Swartzendruber DE and Drewinko B: Prognostic implications of ploidy and proliferative activity in human solid tumors. Cancer Genet Cytogenet 6: 17-28, 1982.
40. Giancotti FR, Dorsett BH, Weaver SC, Bharathur R, Ioachim HL and Barber HRK: Description of an endometrioid ovarian cancer cell line Gynecol Oncol 35: 330-337, 1989.
41. Hills CA, Kelland LR, Abel G, Siracky J, Wilson AP and Harrap KR: Biological properties of ten human ovarian carcinoma cell lines calibration in vitro against four platinum complexes. Brit J Cancer 59: 527-534, 1989.
42. Whang-Pen J, Knutsen T, Douglass EC, Chu E, Ozols RF, Hogan WM and Young RC: Cytogenetic studies in ovarian cancer. Cancer Genet Cytogenet 11: 91-106: 1984.
43. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E and Riou G: Characterization of a human ovarian adenocarcinoma line, IGROV1. in tissue culture and in nude mice. Cancer Res 45: 4970-4979, 1985.
44. Van Niekerk CC, Poels LG, Jap PHK, Smeets DFCM, Thomas CMG., Ramaekers FCS and Vooijs GP: Characterisation of a human ovarian carcinoma cell line, OTN 14, derived from a mucinous cystadenocarcinoma. Int J Cancer 42: 104-111, 1988.
45. Wake N, Hreshchyshyn MM, Piver SM, Matsui S and Sandberg AA: Specific cytogenetic changes in ovarian cancer involving chromosomes 6 and 14. Cancer Res 40: 4512-4518, 1980.
46. Hill BT, Deuchars K, Hosking LK, Ling V and Whelan RDH: Overexpression of P-glvcoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl. Cancer Inst 82: 607-612, 1990.
47. G.P.C.O., Institut de Recherches Internationales Servier. Pharmacological properties of S9788, a new multidrug resistance modulator. Bull Cancer 81: 93-103, 1994.
48. Braakhuis BJM, Hill BT, Dietel M, Kelland LR, Aapro MS, Zoli W and Lelieveld P: In vitro antiproliferative activity of docetaxel (Taxotere®), paclitaxel (Taxol®) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 14: 205-208, 1994.
49. Ringel I and Horwitz SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst 83: 288-291, 1992.
50. Parker RJ, Eastman A, Bostick-Bruton F and Reed E: Acquired cisplatin resistance in human ovarian cancer cells is associated with enhancement repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 87: 772-777, 1991.
51. Van Geel CAJF, Van Den Berg AP and Van Den Aardweg GJMJ: Good correlation between the colorimetric SRB assay and the clonogenic assay for cellular radiosensitivity in different cell types, In. Programme and abstract book of meeting of European Society for radiation biology ESRB and hyperthermic oncology ESHO, 1994, p. 49.
52. Griffon G, Merlin JL and Marchai C: Comparison of sulforhodamine B, tetrazolium and clonogenic assays for in vitro radiosensitivity testing in human ovarian cell lines. Anti-Cancer Drugs, 6: 115-123, 1995.
53. Rofstad EK and Sutherland RM: Radiation sensitivity of human ovarian cell lines in vitro: effects of growth factors and hormones, basement membrane, and intercellular contact. Int J Radiat Oncol Biol Phys 15: 921-929: 1988.
54. Denekamp J: Cell kinetics and radiation biology. Int J Radiat Biol 49: 357-380, 1986.